A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma.

Overview of attention for article published in Journal of Clinical Oncology, May 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

news: 2 news outlets

twitter: 1 X user

Readers on

mendeley: 13 Mendeley

So far, Altmetric has seen 3 news stories from 2 outlets.

ASCO 2025: Key Anticipated Updates Across Cancer Care

Cancer Network, 28 May 2025

One abstract of interest in the gynecologic malignancy space is a late-breaking abstract unveiling findings from the phase 3…

Benefit Observed With Catequentinib to Treat Advanced Synovial Sarcoma

Cancer Network, 05 Jun 2021

Patients with advanced synovial sarcoma (SS) who received treatment with catequentinib (Anlotinib) experienced improved disease…

Catequentinib Shows Promise in Treatment of Advanced Synovial Sarcoma

OncLive, 04 Jun 2021

Results from a single arm of the trial showed that patients treated with catequentinib achieved a median PFS of 2.89 months (95…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.